TY - JOUR
T1 - Approaching the increasing complexity of non-small cell lung cancer taxonomy
AU - Maugeri-Saccà, Marcello
AU - Bartucci, Monica
AU - Pagliuca, Alfredo
AU - Patrizii, Michele
AU - Signore, Michele
AU - de Maria, Ruggero
PY - 2014
Y1 - 2014
N2 - The advent of molecular targeted agents is changing the treatment of solid tumors. In non-small-cell lung cancer, compounds directed against oncogenic proteins offer novel therapeutic opportunities for a fraction of patients whose tumors harbor specific genetic defects. With the increased level of resolution achieved by high-throughput technologies, the taxonomy of lung cancer is rapidly changing. For instance, by cataloguing genetic abnormalities in squamous cell lung cancer the Cancer Genome Atlas Network revealed the existence of multiple molecular entities, each one characterized by specific molecular abnormalities, and by a different spectrum of activated/inactivated molecular networks. Although this increased complexity could be perceived as a further drawback in effective antican-cer therapy, on the other hand the combined interrogation of genomic and proteomic data is expected to provide the whole molecular map of each tumor, and to determine the information flow in the explored biological system. In particular, novel genetic and proteomic approaches are offering the opportunity for matching specific genetic defects and aberrant protein-protein interactions with active pathway-targeted inhibitors. Moreover, the isolation and characterization of a cellular pool endowed with stem-like traits, and able to recapitulate the parental disease in animals, is enabling investigators to recreate the individual patient tumor in the laboratory. In this article, we discuss how novel technologies and cellular and animal models, applied to lung cancer research, hold the potential to foster a new wave of biomarker-driven clinical trials.
AB - The advent of molecular targeted agents is changing the treatment of solid tumors. In non-small-cell lung cancer, compounds directed against oncogenic proteins offer novel therapeutic opportunities for a fraction of patients whose tumors harbor specific genetic defects. With the increased level of resolution achieved by high-throughput technologies, the taxonomy of lung cancer is rapidly changing. For instance, by cataloguing genetic abnormalities in squamous cell lung cancer the Cancer Genome Atlas Network revealed the existence of multiple molecular entities, each one characterized by specific molecular abnormalities, and by a different spectrum of activated/inactivated molecular networks. Although this increased complexity could be perceived as a further drawback in effective antican-cer therapy, on the other hand the combined interrogation of genomic and proteomic data is expected to provide the whole molecular map of each tumor, and to determine the information flow in the explored biological system. In particular, novel genetic and proteomic approaches are offering the opportunity for matching specific genetic defects and aberrant protein-protein interactions with active pathway-targeted inhibitors. Moreover, the isolation and characterization of a cellular pool endowed with stem-like traits, and able to recapitulate the parental disease in animals, is enabling investigators to recreate the individual patient tumor in the laboratory. In this article, we discuss how novel technologies and cellular and animal models, applied to lung cancer research, hold the potential to foster a new wave of biomarker-driven clinical trials.
KW - Cancer stem cells
KW - Loss-of-function genetic screens
KW - Molecular targeted agents
KW - Non-small-cell lung cancer
KW - Reverse-phase protein arrays
UR - http://www.scopus.com/inward/record.url?scp=84903974371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903974371&partnerID=8YFLogxK
U2 - 10.2174/13816128113196660759
DO - 10.2174/13816128113196660759
M3 - Article
C2 - 24138717
AN - SCOPUS:84903974371
VL - 20
SP - 3973
EP - 3981
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
SN - 1381-6128
IS - 24
ER -